Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

The U.S.-based NEW DAY clinical trial enrolled 306 patients with diabetic macular edema who received a single Iluvien ...

Alimera Sciences said Monday that the priority review of Iluvien (fluocinolone acetonide intravitreal insert) will speed up the review time from 10 months to six months. Alimera currently is ...

“From a creative standpoint, the campaign was focused on bringing light to having something like Iluvien and how that would be beneficial to their lifestyle,” Hoffman said. “If you are dealing with ...

Recently, the FDA approved a new option - Iluvien. It is a 3.5 millimeter rod of steroids which is implanted into the eye, and it lasts 3 years.

ILUVIEN revenues should pick up by the end of the year. DME is a chronic disease and there is a desperate need for a sustained release treatment and ILUVIEN fills that need very well.

ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did ...

ILUVIEN is approved in the U.S., Canada, Australia, Kuwait, Lebanon and the U.A.E. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

This note focuses on the implications of the complete response letter (( CRL)) received by Alimera ( ALIM) for Iluvien. This product was developed by pSivida ( PSDV) but was partnered with Alimera ...

Alimera Sciences Inc. failed to win the backing of the U.K.’s health-cost agency for its treatment for the leading cause of blindness associated with diabetes.